Using IlluminOss implants to treat pelvic fractures in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project evaluates the effectiveness of the IlluminOss pelvic implants in patients suffering from pelvic metastatic disease, focusing on those with pain and risk of pathologic fractures. The study aims to confirm significant reductions in pain and improvements in function for patients with non-displaced or minimally displaced fractures, as well as geriatric patients with pelvic fragility fractures. By utilizing prophylactic fixation, the study seeks to minimize symptoms and enhance quality of life for this vulnerable population. The research will analyze clinical and radiographic features to better predict fracture risk and the need for intervention.

Why it matters

Who can join: the full rules

Inclusion criteria:

Patients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. It is a decision made by the treating surgeon separately from research and prior to mention of the study.

1. Patient is a skeletally mature patient 21 years of age or older (closed epiphyseal plates) who receiving the FDA-approved IlluminOss Pelvic Implant
2. IlluminOss Pelvic Implant is intended to treat pain due to impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis secondary to metastatic malignancy, multiple myeloma, lymphoma, or radiation osteitis or a pelvic fragility fracture in a geriatric patients (age 65 or older)
3. VAS Pain Score ≥ 30 on 0 to 100 scale

Exclusion criteria:

1. Patient is uncooperative, or patient incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder)
2. Patient is a prisoner
3. Patient is deemed surgically unfit by the medical oncology service

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Kevin Raskin, MD
• Email: kraskin@mgh.harvard.edu
• Phone: 617-724-3700

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• IL-22BP mRNA peptide therapy for advanced solid tumors

  A phase 1 study tests a new peptide-delivered IL-22BP mRNA treatment to see if it is safe and if it has any early signs of shrinking or stopping advanced solid tumors in adults.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07583654

• Symptom Management and Survivorship Coaching for Advanced Cancer Patients and Caregivers

  This study tests a 10-week Symptom Management and Survivorship Handbook plus telephone coaching to help metastatic cancer patients and their caregivers manage symptoms and stay connected.

  Recruiting University of Arizona · Tucson, Arizona · NCT07415564

• Comparing two types of radiation therapy for painful bone metastases

  This study is testing whether a new type of radiation therapy can help people with painful bone cancer feel better than the standard treatment.

  Recruiting at 12 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 11 other locations · NCT06391242

• Registry to monitor malnutrition in cancer patients

  This study is trying to see how tracking nutrition in newly diagnosed or treated cancer patients can help improve their health and quality of life.

  Recruiting at 13 sites Fondazione IRCCS Policlinico San Matteo di Pavia · Bari, BA and 15 other locations · NCT06337019

• Comparing surgical methods for metastatic pathologic fractures

  This study is testing which of three surgical methods works best to help people with painful fractures caused by cancer so they can feel better and move around more easily.

  Recruiting Ankara University · Ankara, altindag · NCT05825456

• Testing the safety and dosing of zeaxanthin for advanced cancer treatment

  This study is testing how much zeaxanthin, a natural compound, can be safely given to people with advanced cancer to see if it helps them without causing bad side effects.

  Recruiting Phase 1 Valley Health System · Paramus, New Jersey · NCT05232409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.